Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study

摘要: Patients with moderate-to-severe plaque-type psoriasis exhibit increased cardiovascular mortality. Recent publications point towards psoriasis-induced insulin resistance as an important pathomechanism driving comorbidity in these patients. As the hormonal status general and sex hormone-binding globulin (SHBG) particular serve sensitive indicators for resistance, we analysed parameters context of a set multiple additional clinical laboratory measurements cohort male Of 33 consecutively enrolled patients receiving continuous systemic therapy their psoriasis, 23 whom all could be collected over 24-week treatment period were included this analysis. At baseline, testosterone levels varied between 212 660 ng/ml (median: 377.0), SHBG 11.9 46.0 nmol/l 29.2), thus documenting lack hypogonadism among Clinically, 19/23 experienced at least 50% reduction PASI under therapy. Using multivariate regression model to further analyse sub-group responding treatment, hs-CRP, PASI, leptin resistin improved effective anti-inflammatory therapy, losing significant influence on SHBG. performed well biomarker inflammation Its improvement, serum levels, most likely reflects state reduced risk undergoing Long-term safety data, generated e.g. from registries, are needed assess whether effect translates into